Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study.
Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study.
复制标题
DOI：
10.1007/s10194-011-0338-0
复制
发表时间：
2011-10
影响因子：
7.4
通讯作者：
Sette, Giuliano
中科院分区：
文献类型：
--
作者：
Pizzolato, Raffaella;Villani, Veronica;Prosperini, Luca;Ciuffoli, Alessandro;Sette, Giuliano
偏头痛是一种常见的神经系统疾病，流行病学研究已经证明了其高度的社会和经济影响。不幸的是，预防性治疗通常不足以显著降低偏头痛的频率，或者不能很好地耐受。抗癫痫药物越来越多地用于偏头痛的预防。然而，关于普瑞巴林在偏头痛患者中的疗效和耐受性的数据仍然缺乏。我们的目的是评价普瑞巴林治疗偏头痛的疗效和耐受性。我们招募了47名患者，他们以75 mg/天的剂量开始普瑞巴林治疗，如果耐受，则滴定至300 mg/天。共有6名患者（13%）在服用普瑞巴林期间报告了一种或多种副作用;然而，其中3名患者停用普瑞巴林，因为副作用无法忍受且持续存在。治疗1个月和3个月后，与基线相比，偏头痛频率明显减少（p < 0.001）。在治疗的第一个月内增加剂量的患者中观察到更大的频率降低。我们的数据表明，普瑞巴林可能是耐受性良好，并可能代表一种替代的预防性治疗偏头痛。本研究的局限性是样本量小和非对照、开放标签设计;需要进一步的随机病例对照研究来证实我们的发现。
Migraine is a common neurological disorder and epidemiological studies have documented its high social and economic impact. Unfortunately, preventive treatment is often insufficient to substantially reduce migraine frequency or it is not well tolerated. Antiepileptic drugs are increasingly used in migraine prevention. However, data on efficacy and tolerability of pregabalin in patients with migraine are still lacking. Our aim was to evaluate efficacy and tolerability of pregabalin in patients with migraine. We recruited 47 patients who started pregabalin at 75 mg/day, which was titrated to 300 mg/day as tolerated. A total of six patients (13%) reported one or more side effects during the intake of pregabalin; however, three of them discontinued pregabalin, because side effects were intolerable and persistent. Statistically significant reduction in migraine frequency compared to baseline (p < 0.001) was evident after 1 and 3 months of treatment. A greater frequency reduction was observed in those patients who increased the dosage within the first month of therapy. Our data suggest that pregabalin may be well tolerated and may represent an alternative preventive treatment in migraneurs. Limitations of the present study were a small sample size and an uncontrolled, open-label design; further randomized case–control studies are warranted to confirm our findings.
登录
查看更多内容
影响因子：
9.9
作者：
Lipton, RB;Scher, AI;Stewart, WF
通讯作者：
Stewart, WF
影响因子：
3.2
作者：
Tassone, Daniel M.;Boyce, Eric;Nuzum, Donald
通讯作者：
Nuzum, Donald
影响因子：
2.7
作者：
Buchanan, TM;Ramadan, NM
通讯作者：
Ramadan, NM
影响因子：
5
作者：
Ramadan, Nabih M.
通讯作者：
Ramadan, Nabih M.
影响因子：
5.6
作者：
Ben-Menachem, E
通讯作者：
Ben-Menachem, E